Cancer Immunotherapy
Blocking the PD-1 pathway can restore antitumor activity and has produced durable responses in some cancers, with benefits and risks varying by patient and tumor.
Blocking the PD-1 pathway can restore antitumor activity and has produced durable responses in some cancers, with benefits and risks varying by patient and tumor.